知搜-全球专利检索

  1. 登录
  2. 注册
发明授权
CN1944463B 具有α干扰素活性的融合蛋白及其编码基因与应用 失效 - 权利终止

具有α干扰素活性的融合蛋白及其编码基因与应用
摘要：
本发明公开了一种具有α干扰素活性的融合蛋白及其编码基因与应用。其目的是提供一种具有α干扰素活性的融合蛋白及其编码基因，以及该融合蛋白的表达方法和在制备提高机体免疫力药物中的应用。该融合蛋白是在人IFNα-2b的羧基端连接有人IgG Fc-γ1或人IgG Fc-γ2的融合蛋白；所述人IFNα-2b具有序列表中SEQ ID №：13的氨基酸残基序列；所述人IgG Fc-γ1为野生型人IgG Fc-γ1或其突变体；所述人IgG Fc-γ2为野生型人IgG Fc-γ2或其突变体。该融合蛋白具有以下优点：1)α干扰素活性高；2)半衰期长；3)ADCC杀伤作用小。本发明在医学和生物制药领域，尤其是提高机体免疫力药物的制备领域具有较大的实际意义和广阔的应用前景。
摘要（英）：

The present invention discloses one kind of fusion protein with alpha-interferon activity and its coding gene, expression mode and application in preparing medicine for raising body's immunity. The fusion protein is human IFN-alpha-2b fusion protein with human IgG Fc-gamma-1 or human IgG Fc-gamma-2 connected to the carboxyl group end, the human IFN-alpha-2b has the amino acid residue sequence as shown in SEQ ID No. 13 of the sequence list, the human IgG Fc-gamma-1 is wild human IgG Fc-gamma-1 or its mutant, and the human IgG Fc-gamma-2 is wild human IgG Fc-gamma-2 or its mutant. The fusion protein has the following advantages: high alpha-interferon activity, long half life and small ADCC damaging effect. The present invention is significant and possesses wide application foreground in medicine and biomedicine preparing fields, especially in preparing medicine for raising immunity.

公开/授权文献
0/0